Microbot Medical to Highlight Progress and Recent Achievements at H.C. Wainwright 6th Annual Israel Conference
November 09 2020 - 7:00AM
Microbot Medical Inc. (Nasdaq: MBOT) announced that Harel Gadot,
the Company’s CEO, President and Chairman, will be providing an
overview of the Company, as well as recent progress and
achievements at the H.C. Wainwright 6th Annual Israel Conference,
on November 12, 2020 at 2:00pm ET. In addition to the presentation,
the conference will feature virtual one-on-one meetings with
Microbot Medical’s executives and institutional investors are
invited to request meeting times at meetings@hcwco.com.
“Our team has made significant progress, and we
will continue to leverage these developments toward a clear
clinical and regulatory path to future commercialization,”
commented Mr. Gadot. “These reinforce our vision, commitment, and
dedication and I am excited to share the Microbot story and
highlight our achievements with investors.”
A live webcast and subsequent archived replay of
the Company’s presentation may be accessed via the ‘Investors’
section, under ‘Presentation + Resources’ of the Company’s website
at www.microbotmedical.com.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, focused primarily on
both natural and artificial lumens within the human body.
Microbot’s current proprietary technological platforms provide the
foundation for the development of a Multi Generation Pipeline
Portfolio (MGPP).
Microbot Medical was founded in 2010 by Harel
Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of
improving clinical outcomes for patients and increasing
accessibility through the use of micro-robotic technologies.
Further information about Microbot Medical is available at
http://www.microbotmedical.com.
Safe Harbor
Statements pertaining to the registered direct
offering, timing, the amount and anticipated use of proceeds and
statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for Microbot Medical Inc. and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions and
the satisfaction of customary closing conditions, risks inherent in
the development and/or commercialization of potential products,
including LIBERTY, the outcome of its studies to evaluate the SCS
and other existing and future technologies, uncertainty in the
results of pre-clinical and clinical trials or regulatory pathways
and regulatory approvals, uncertainty resulting from the COVID-19
pandemic, need and ability to obtain future capital, and
maintenance of intellectual property rights. Additional information
on risks facing Microbot Medical can be found under the heading
“Risk Factors” in Microbot Medical’s periodic reports filed with
the Securities and Exchange Commission (SEC) and in the prospectus
supplement related to the registered direct offering to be filed
with the SEC, which are or will be available on the SEC’s web site
at www.sec.gov. Microbot Medical disclaims any intent or obligation
to update these forward-looking statements, except as required by
law.
Investor Contact:
Michael PolyviouEVC Group
mpolyviou@evcgroup.com732-933-2754
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Apr 2023 to Apr 2024